Title	**Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines**
Authors	Nicholas A Kennedy, PhD[1,2]*, Simeng Lin, MBChB[1,2*], James R Goodhand, MBBS[1,2]*, Neil Chanchlani, MBChB[1,2], Ben Hamilton MBBS[1,2], Claire Bewshea, MSc[2], Rachel Nice, MSc[2,3], Desmond Chee, MBBS[1,2], JR Fraser Cummings, DPhil[4], Aileen Fraser, MSc[5], Peter M Irving, MD[6,7], Nikolaos Kamperidis, MD[8], Klaartje B Kok, PhD[9,10], Christopher A Lamb, PhD[11,12], Jonathan Macdonald, BM[13,14], Shameer J Mehta, MD[15], Richard CG Pollok, PhD[16,17], Tim Raine, PhD[18], Philip J Smith, MBBS[19], Ajay M Verma, MD[20], Timothy J McDonald, PhD [2,3], Shaji Sebastian, MD[21, 22], Charlie W Lees, PhD[23,24], Nick Powell, PhD[25,26*], Tariq Ahmad, DPhil[1,2*], Contributors to the CLARITY IBD study *denotes equal contribution
Affiliations	[1] Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK [2] Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, UK [3] Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK [4] Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK [5] Department of Gastroenterology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK [6] Department of Gastroenterology, Guy's and St Thomas' NHS

Foundation Trust, London, UK

[7]School of Immunology & Microbial Sciences, King's College London, London, UK

[8] Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK

[9] Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

[10] Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK

[11] Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

[12] Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

[13] Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK

[14] School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK

[15] Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK

[16] Department of Gastroenterology, St George's University Hospital NHS Foundation Trust, London, UK

[17] Institute for Infection & Immunity, St George's, University of London, London, UK

[18] Department of Gastroenterology, Addenbrooke's Hospital, Cambridge

	University Hospitals NHS Foundation Trust, Cambridge, UK [19] Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK [20] Department of Gastroenterology, Kettering General Hospital, Kettering, UK [21] IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK [22] Hull York Medical School, University of Hull, Hull, UK [23] Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK [24] Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Gastroenterology, Western General Hospital, Edinburgh, UK [25] Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK [26] Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Address for correspondence	Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK tariq.ahmad1@nhs.net
Key words	SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, CLARITY
Running title	Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines.
Word count	2939

1

Research in context

Evidence before this study

Faced with further surges of SARS-CoV-2 infection, a growing number of countries, including the UK, have opted to delay second vaccine doses for all people. This strategy trades maximal effectiveness against a lower level of protective immunity across more of the at-risk population.

We have previously shown that seroprevalence, seroconversion in PCR-confirmed cases, and the magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab- compared with vedolizumab-treated patients. Whether single-doses of vaccines are effective in patients treated with anti-TNF therapies is unknown.

We searched PubMed from 25 November 2019 to 23 March 2021 with the terms “anti-tumour necrosis factor” or “anti-integrin” or “infliximab” or “adalimumab” or “vedolizumab” or “biological therapy” or “biologic therapy” AND “SARS-CoV-2" or “coronavirus” or “COVID-19” or AND “seroprevalence” or “seroconversion” or “antibody” or “antibody response” or “magnitude” or “immunogenicity” AND “vaccine” or “vaccination” or “immunisation” or “immunization” or “ChAdOx1 nCoV-19" or “BNT162b2” or “mRNA-1273”, without restriction on language.

Serological responses to SARS-CoV-2 vaccines have been reported in registration trials and small observational cohorts of healthy volunteers. Two small studies, including one unpublished preprint, found that COVID-19 vaccine immunogenicity rates were lower in transplant recipients and patients with malignancy receiving immunosuppressive therapy, and fewer patients treated with potent immunosuppressants seroconverted than healthy controls. No studies have assessed the effect of anti-TNF therapy on immunogenicity following SARS-CoV-2 vaccination.

24 ***Added value of this study***

25 To test if anti-TNF drugs attenuate serological responses to primary SARS-CoV-2 vaccines, we
26 analysed anti-SARS-CoV-2 spike (S) antibody concentrations and seroconversion rates in 1293
27 patients with inflammatory bowel disease who received primary vaccinations with either the
28 ChAdOx1 nCoV-19 or BNT162b2 vaccines. 865 were treated with the anti-TNF drug infliximab and
29 outcomes were compared to a reference cohort of 428 patients treated with vedolizumab, a gut
30 selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired systemic
31 immune responses.

32 Anti-SARS-CoV-2 antibody levels and rates of seroconversion were lower following primary
33 vaccination with both the BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD treated
34 with infliximab compared to vedolizumab. Older age, immunomodulator use, Crohn's disease
35 (versus ulcerative colitis or inflammatory bowel disease unclassified), and current smoking were
36 associated with lower anti-SARS-CoV-2 antibody concentrations, irrespective of vaccine type. Non-
37 white ethnicity was associated with higher anti-SARS-CoV-2 (S) antibody concentrations following
38 primary vaccination with both vaccines. Antibody concentrations and seroconversion rates were
39 higher in patients with past SARS-CoV-2 infection prior to a single-dose of either vaccine, and after 2
40 doses of the BNT162b2 vaccine.

41 ***Implications of the available evidence***

42 Our findings have important implications for patients treated with anti-TNF therapy, particularly for
43 those also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine
44 exposes these patients to a potential increased risk of SARS-CoV-2 infection. However, higher rates
45 of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even in the presence of
46 TNF blockade, suggest that all patients receiving these drugs should be prioritized for optimally

timed second doses. Until patients receive a second vaccine dose, they should consider that they are not protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and shielding if appropriate. Even after two antigen exposures, a small subset of patients failed to mount an antibody response. Antibody testing and adapted vaccine schedules should be considered to protect these at-risk patients.

Abstract

Background

Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single-dose of a SARS-CoV-2 vaccine.

Methods

Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared to a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations 3-10 weeks after vaccination in patients without evidence of prior infection. Secondary outcomes were seroconversion rates, and antibody responses following past infection or a second dose of the BNT162b2 vaccine.

Findings

Geometric mean [SD] anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6·0 U/mL [5·9] vs 28·8 U/mL [5·4] P<0·0001) and ChAdOx1 nCoV-19 (4·7 U/mL [4·9]) vs 13·8 U/mL [5·9] P<0·0001) vaccines. In our multivariable models, antibody concentrations were lower in infliximab- compared to vedolizumab-treated patients who received the BNT162b2 (fold change [FC] 0·29 [95% CI 0·21, 0·40], p<0·0001) and ChAdOx1 nCoV-19 (FC 0·39 [95% CI 0·30, 0·51], p<0·0001) vaccines. In both models, age ≥ 60 years, immunomodulator use, Crohn's disease, and smoking were associated with lower, whilst non-white ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion rates after a single-dose of either vaccine were higher in patients with prior SARS-CoV-2 infection and after two doses of BNT162b2 vaccine.

Interpretation

Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab.

Funding

Royal Devon and Exeter and Hull University Hospital Foundation NHS Trusts. Unrestricted educational grants: F. Hoffmann-La Roche AG (Switzerland), Biogen GmbH (Switzerland), Celltrion Healthcare (South Korea) and Galapagos NV (Belgium).

Introduction

Limited SARS-CoV-2 vaccine supplies and pressure on critical care services have forced governments to prioritise primary vaccination to vulnerable groups. In the United Kingdom, second vaccine doses have also been delayed, trading maximal effectiveness for a lower level of protective immunity across a greater proportion of the most at-risk population.[1] Consequently, more than half of the adult population have received a single-dose of either the RNA vaccine, BNT162b2 (Pfizer/BioNTech) or the adenovirus-vector vaccine, ChAdOx1 nCoV-19 (Oxford/AstraZeneca). Faced with further surges of SARS-CoV-2 infection, a growing number of other countries have also opted to delay second vaccine doses.[2,3]

The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are chronic immune-mediated inflammatory diseases (IMIDs) that affect about 1% of the UK population.[4,5] Treatment typically requires immunosuppression with immunomodulators (azathioprine, mercaptopurine, and methotrexate) and/or biological therapies that target disease relevant cytokines or the immune cells that produce them. Anti-tumour necrosis factor (TNF) drugs, such as infliximab and adalimumab, are the most frequently prescribed biopharmaceuticals used in the treatment of IMIDs. These drugs impair immunogenicity following pneumococcal,[6] influenza,[7] and hepatitis B[8] vaccinations and increase the risk of serious infection, most notably with respiratory pathogens.[9] Conversely, vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody is not associated with increased susceptibility to systemic infection or attenuated serological responses to vaccination.[10]

We have recently reported that seroprevalence, seroconversion in PCR-confirmed cases, and the magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab-compared with vedolizumab-treated patients.[11] We hypothesised that, following at least a single-dose with BNT162b2 or ChAdOx1 nCoV-19 vaccine, serological responses would be similarly

110 impaired in patients treated with infliximab compared to vedolizumab arguing against delaying
111 second doses in these patients.
112
113 We aimed to define, in patients with IBD who had received a COVID-19 vaccination, whether biologic
114 class and concomitant use of an immunomodulator impact:
115 i) anti-SARS-CoV-2 spike (S) antibody levels
116 ii) rates of seroconversion
117 iii) antibody responses in patients who had previously been infected with SARS-CoV-2 or who
118 had two doses of vaccine
119

120 ## Methods

121 *Study design and participants*

122 impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY) IBD is a UK wide,
123 multicentre, prospective observational cohort study investigating the impact of infliximab and
124 vedolizumab and/or concomitant immunomodulators (azathioprine, mercaptopurine, and
125 methotrexate) on SARS-CoV-2 acquisition, illness, and immunity in patients with IBD.

126 Study methods have been described in detail previously.[11] In brief, consecutive patients were
127 recruited at the time of attendance at infusion units from 92 National Health Service (NHS) hospitals
128 across the UK between 22nd September 2020 and 23rd December 2020 (Supplementary pp 2 - 17).
129 The eligibility criteria were age 5 years and over, a diagnosis of IBD, and current treatment with
130 infliximab or vedolizumab for 6 weeks or more, with at least one dose of drug received in the
131 previous 16 weeks. Patients were excluded if they had participated in a SARS-CoV-2 vaccine trial.

132 Follow-up visits were timed to coincide with biologic infusions and occurred approximately eight-
133 weekly. Here, we report vaccine-induced antibody responses at first study visit after primary
134 vaccination, and where possible, after two doses. Participants were eligible for inclusion in our
135 vaccine immunogenicity analysis if they had had a SARS-CoV-2 antibody test within the first ten
136 weeks after their primary vaccination with any of the available SARS-CoV-2 vaccines.

137 The Surrey Borders Research Ethics committee approved the study (REC reference: 20/HRA/3114) in
138 September 2020. Patients were included after providing informed, written consent. The sponsor was
139 the Royal Devon and Exeter NHS Foundation Trust. The protocol is available online at
140 https//www.clarityibd.org. The study was registered with the ISRCTN registry, ISRCTN45176516.

141 *Procedures*

142 Variables recorded by participants were demographics (age, sex, ethnicity, comorbidities, height and
143 weight, smoking status, and postcode), IBD disease activity (PRO2), SARS-CoV-2 symptoms aligned to
144 the COVID-19 symptoms study (symptoms, previous testing, and hospital admissions for COVID-19),
145 and vaccine uptake (type and date of primary vaccination). Study sites completed data relating to
146 IBD history (age at diagnosis, disease duration, and phenotype according to the Montreal
147 classifications, previous surgeries, and duration of current biologic and immunomodulator
148 therapy).[11] We linked our data by NHS number or Community Health Index to Public Health England,
149 Scotland, and Wales who archive dates and results of all SARS-CoV-2 PCR tests undertaken. Data
150 were entered electronically into a purpose-designed REDCap database hosted at the Royal Devon
151 and Exeter NHS Foundation Trust.[12] Participants without access to the internet or electronic device
152 completed their questionnaires on paper case record forms that were subsequently entered by local
153 research teams.

154 Laboratory analyses were performed at the Academic Department of Blood Sciences at the Royal
155 Devon and Exeter NHS Foundation Trust. To determine antibody responses specific to vaccination
156 we used the Roche Elecsys Anti-SARS-CoV-2 spike (S) immunoassay[13] alongside the nucleocapsid (N)
157 immunoassay.[14] This double sandwich electrochemiluminescence immunoassay uses a recombinant
158 protein of the receptor binding domain on the spike protein as an antigen for the determination of
159 antibodies against SARS-CoV-2. Sample electrochemiluminescence signals are compared to an
160 internal calibration curve and quantitative values are reported as units (U)/mL.

161 In-house assay validation experiments demonstrated:

162 i) The intra-assay and inter-assay coefficient of variation were 1·3% and 5·6%, respectively

163 ii) Anti-SARS-CoV-2 (S) antibodies were stable in uncentrifuged blood and serum at ambient
164 temperature for up to seven days permitting postal transport

165 iii) No effect was observed on recovery of anti-SARS-CoV-2 (S) antibodies following four
166 freeze/thaw cycles

167 iv) No analytical interference was observed for the detection of anti-SARS-CoV-2 (S) with
168 infliximab or vedolizumab up to 10,000 mg/L and 60,000 mg/L, respectively, or with anti-
169 drug antibodies to infliximab or vedolizumab up to 400 AU/mL and 38 AU/mL, respectively
170 (data not shown).

171 At entry to CLARITY IBD and at follow-up visits, all patients were tested for previous SARS-CoV-2
172 infection using the Roche Elecsys anti-SARS-CoV-2 (N) immunoassay. Because antibody responses
173 are impaired following PCR-confirmed natural infection we set a threshold of 0·25 times the cut-off
174 index (COI) at or above which patients were deemed to have had prior infection.[11] We defined a
175 second threshold of 0·12 times the COI, below which patients were deemed to have no evidence of
176 prior infection. Patients with a PCR test confirming SARS-CoV-2 infection at any time prior to
177 vaccination were deemed to have evidence of past infection irrespective of any antibody test result.

178 *Outcomes*

179 Our primary outcome was anti-SARS-CoV-2 anti-spike (S) protein receptor-binding protein antibodies
180 three to ten weeks after primary vaccination.

181 Secondary outcomes were:

182 (i) proportion of participants with seroconversion, defined by a threshold which has been
183 associated with pseudoneutralisation in vitro.

184 (ii) antibody concentrations and seroconversion in patients with PCR or serological evidence
185 of past SARS-CoV-2 infection at, or prior, to the post-vaccination serum sample.

186 (iii) antibody concentrations and seroconversion after two doses of vaccine.

187

188 *Statistical Analysis*

189 The sample size for CLARITY IBD was based on the number of participants required to demonstrate a
190 difference in the impact of infliximab and vedolizumab on seroprevalence and seroconversion
191 following SARS-CoV-2 infection, with an estimated background seroprevalence of 0·05. We
192 calculated that a sample of 6970 patients would provide 80% power to detect differences in the
193 seroprevalence of anti-SARS-CoV-2 antibodies in infliximab- compared with vedolizumab-treated
194 patients, whilst controlling for immunomodulator status at the 0·05 significance level. We stored and
195 then analysed all serum samples as soon as the Roche Elecsys anti-SARS-CoV-2 (S) immunoassay was
196 established in our laboratory.

197 Statistical analyses were undertaken in R 4·0·4 (R Foundation for Statistical Computing, Vienna,
198 Austria). All tests were two tailed and p-values <0·05 were considered significant. We included
199 patients with missing clinical data in analyses for which they had data and have specified the
200 denominator for each variable. Anti-S antibody concentrations are reported as geometric means and
201 standard deviations. Other continuous data are reported as median and interquartile range, and
202 discrete data as numbers and percentages, unless otherwise stated.

203 Univariable analyses, using t-tests of log-transformed anti-SARS-CoV-2 (S) antibody concentration
204 and Spearman's rank correlation coefficients, were used to identify demographic, disease, vaccine,
205 and treatment-related factors associated with the concentration of anti-SARS-CoV-2 (S) antibodies.
206 To test our primary outcome, we used multivariable linear regression models to identify factors
207 independently associated with log anti-SARS-CoV-2 (S) levels. A priori, we included age, ethnicity,
208 biologic medication, and immunomodulator use. No stepwise regression was performed. Results are
209 presented after exponentiation, so that the coefficients of the model correspond to the fold change
210 associated with each binary covariate. For age, a cut-off was chosen based on graphical inspection of

211 the relationship between age and anti-SARS-CoV-2 (S) antibody concentrations. We also report the
212 proportions of patients who seroconverted following vaccination. Seroconversion was defined by an
213 optimized cut-off of 15 U/mL, with a positive predictive value of 99·1%, based on the correlation
214 between receptor-binding domain antibodies and the cPass SARS-CoV-2 surrogate virus
215 neutralisation test (internal data, Roche Diagnostics GmbH, Germany).[15,16] We conducted sensitivity
216 analyses to compare antibody responses stratified by participants with serological or PCR evidence
217 of SARS-CoV-2 infection at any time prior to vaccination and in those who had received 2 doses of
218 vaccine.

219 *Role of the funding source*

220 CLARITY IBD is an investigator-led, UK National Institute for Health Research COVID-19 urgent public
221 health study, funded by the Royal Devon and Exeter NHS Foundation Trust, Hull University Teaching
222 Hospital NHS Trust, and by unrestricted educational grants from F. Hoffmann-La Roche AG
223 (Switzerland), Biogen GmbH (Switzerland), Celltrion Healthcare (South Korea) and Galapagos NV
224 (Belgium). None of our funding bodies had any role in study design, data collection or analysis,
225 writing, or decision to submit for publication.

226 Results

227 Between September 22nd 2020 and December 23rd 2020, 7226 patients were recruited to the
228 CLARITY study from 92 UK hospitals.[11] For the primary immunogenicity analyses we included 865
229 infliximab- and 428 vedolizumab-treated participants without evidence of prior SARS-CoV-2
230 infection, who had received uninterrupted biologic therapy since recruitment and had an antibody
231 test between 21 and 70 days after primary vaccination. Participant characteristics are shown in Table
232 1.

233 *Anti-SARS-CoV-2 (S) antibody level following primary COVID-19 vaccine*

234 Geometric mean [geometric SD] anti-SARS-CoV-2 (S) antibody concentrations were lower in patients
235 treated with infliximab than vedolizumab, following both the BNT162b2 (6·0 U/mL [5·9] vs 28·8
236 U/mL [5·4] P<0·0001) and ChAdOx1 nCoV-19 (4·7 U/mL [4·9] vs 13·8 U/mL [5·9] P<0·0001) vaccines
237 (Figure 1). Amongst infliximab-treated patients, the geometric mean [geometric SD] anti-SARS-CoV-2
238 (S) antibody concentrations were also lower in patients treated with a concomitant
239 immunomodulator. Additional univariable analyses are shown in Table 2.
240

241 In our multivariable models, anti-SARS-CoV-2 antibody concentrations were lower in infliximab-
242 compared with vedolizumab-treated patients in participants who received the BNT162b2 (fold
243 change [FC] 0·29 [95% CI 0·21, 0·40], p<0·0001) and ChAdOx1 nCoV-19 [FC] 0·39 [95% CI 0·30, 0·51],
244 p<0·0001) vaccines. Age ≥ 60 years, immunomodulator use, and current smoking were also
245 independently associated with lower anti-SARS-CoV-2 antibody concentrations in participants who
246 received either vaccine. Conversely, non-white ethnicity was associated with higher antibody
247 concentrations following both vaccines (figure 2).
248

249 The 15-day rolling geometric mean of anti-SARS-CoV-2 antibody concentrations are shown in
250 Figure 3. Three weeks after vaccination, we observed lower anti-SARS-CoV-2 (S) antibody
251 concentrations in infliximab- compared to vedolizumab-treated patients following both vaccines.
252 Sustained serological responses were observed in the vedolizumab- but not infliximab-treated
253 patients.

254

255

256 *Seroconversion following primary COVID-19 vaccination*

257 The lowest rates of seroconversion were observed in participants treated with infliximab in
258 combination with an immunomodulator with both the BNT162b2 (27.1%; 65/240) or ChAdOx1
259 nCoV-19 (20.2%; 60/297) vaccines. Highest rates of seroconversion were seen in patients treated
260 with vedolizumab monotherapy who received the BNT162b2 (74.7%;124/166) or ChAdOx1 nCoV-19
261 (57.3%; 94/164) vaccines (Figure 4).

262 *Antibody responses following prior SARS-CoV-2 infection and two COVID-19 vaccine doses*

263 Amongst participants with SARS-CoV-2 infection prior to vaccination, geometric mean [SD] anti-
264 SARS-CoV-2 (S) antibody concentrations were lower in infliximab- compared with vedolizumab-
265 treated patients in those who received a single-dose of BNT162b2 (191 U/mL [12·5] vs 1865 U/mL
266 [8·0] P<0·0001) and ChAdOx1 nCoV-19 (185 U/mL [9·3] vs 752 [12·5] P=0·046) vaccines. In both
267 infliximab- and vedolizumab-treated patients, antibody concentrations following vaccination were
268 higher than those observed in patients without prior infection (Figure 5). Overall, across both
269 vaccines, 82% (76/93) patients treated with infliximab and 97% (33/34) patients treated with
270 vedolizumab seroconverted (p=0·041).

271 Antibody responses were assessed in 27 patients following two doses of the BNT162b2 vaccine
272 without serological evidence of prior infection (Figure 5). In both infliximab- and vedolizumab-
273 treated patients, antibody levels and seroconversion rates were higher after two doses than after a
274 primary vaccine without prior infection (geometric means infliximab 158 U/mL [7·0] vs 6·0 U/mL
275 [5·9], p<0·0001; vedolizumab 562 U/mL [11·5] vs 28·8 U/mL [5·4], p = 0·018). After second-vaccine
276 doses 85% (17/20) infliximab- and 86% (6/7) vedolizumab-treated patients seroconverted (p=0·68).

277

278 ## Discussion

279 ***Key results***

280 We have shown that anti-SARS-CoV-2 spike antibody levels and rates of seroconversion are lower
281 following vaccination with a single-dose of either BNT162b2 or ChAdOx1 nCoV-19 vaccines in
282 patients with IBD treated with infliximab than vedolizumab. Combination therapy with an
283 immunomodulator further attenuated immunogenicity to both vaccines in infliximab-treated
284 patients. Reassuringly, however, a second exposure to antigen, either by vaccination after infection,
285 or a second dose of vaccine led to seroconversion in most patients.

286 Direct comparisons between our data and the antibody responses reported in the vaccine
287 registration trials are limited by differences in the assays used to define immunogenicity and the
288 adoption of different thresholds to define seroconversion. No adequately powered studies have
289 reported the effect of anti-TNF drugs on vaccine responses.[17] Our findings are similar, however, to
290 recent reports of the immunogenicity of the BNT162b2 and mRNA-1273 vaccines in transplant
291 recipients and in patients with malignancy treated with anti-metabolite immunosuppression,
292 conventional chemotherapy or immune checkpoint inhibitors.[18,19] The authors showed fewer
293 patients treated with potent immunosuppressants seroconverted than healthy controls.
294 Importantly, as we have also shown here, second vaccine doses led to seroconversion in the cancer
295 cohort. However, even after two antigen exposures, a small subset of patients (18% [20/113]
296 infliximab-treated patients and 5% [2/41] vedolizumab-treated patients) in our study failed to mount
297 an antibody response. To identify this group, and because the sustainability of antibody responses
298 overall is unknown, serial measurement of antibody responses are indicated.

299 Urgent research is needed to understand the factors linked to non-response and how to potentiate
300 long-term immunogenicity in this group. Strategies to be tested include the manipulation of timing

301 of second vaccinations of second vaccinations, booster doses, the use of adjuvants and/or switching
302 between vaccines with different mechanisms of action. Moreover, from the public health
303 standpoint, recent case reports have shown that potent immunosuppression leads to chronic
304 nasopharyngeal carriage and evolution of new SARS-CoV-2 variants.[20,21] Whether this occurs in
305 patients treated with anti-TNF therapy with impaired antibody response is an important conceptual
306 concern.

307 Our data has other important findings relating to SARS-CoV-2 vaccine responses. We have
308 demonstrated that antibody responses to SARS-CoV-2 vaccines are reduced in older individuals and
309 current smokers. Smoking has also been associated with lower antibody responses to hepatitis B
310 vaccination and faster decay of antibodies after vaccination with live attenuated and trivalent
311 influenza vaccines.[22,23] We have also demonstrated higher antibody responses to both the BNT162b2
312 and ChAdOx1 nCoV-19 vaccines in non-white participants. This might be explained by differences in
313 genetics,[24] gut microbiota,[25] nutrition,[26] and priming of the immune system by prior exposure to
314 SARS-CoV-2 not detected by our pre-vaccination antibody test. Lower antibody concentrations were
315 also observed in patients with Crohn's disease when compared to patients with ulcerative colitis or
316 IBD-unclassified. Despite evidence of defective mucosal immunity, previous vaccine studies involving
317 patients with Crohn's disease or ulcerative colitis have not shown attenuated antibody responses to
318 vaccination in the absence of concomitant immunomodulator or biologic therapy.[6,7]

319 The cytokine TNF shapes multiple aspects of host immune responses, including T-cell dependent
320 antibody production. Genetic ablation of TNF results in disruption of B-cell follicles in germinal
321 centres with defective induction of antigen-induced antibody production.[27,28] These biological
322 properties may in part explain why TNF blockade is clinically beneficial in IMIDs, but also explain the
323 increased risk of serious and opportunistic infections and impaired response to other vaccines.

Whilst our data are biologically plausible, we acknowledge the following limitations of our study. We have used an electrochemiluminescence immunoassay to measure antibody concentrations rather than using a neutralising assay. Although neutralisation assays are considered more biologically relevant, it is now established that anti receptor-binding domain antibodies, which target the spike protein component that engages host cells through ligation of angiotensin-converting enzyme 2, closely correlate with neutralisation assays.[29,30] Second, we only assessed humoral responses to infection, and it is likely that protective immunity additionally requires induction of memory T cell responses. Finally, we investigated one anti-TNF drug, infliximab, only. However, we suspect that our key findings will apply to other anti-TNF biologics used to treat IMIDs, including adalimumab, certolizumab, golimumab, and etanercept. Further observational data will be required to elucidate the impact of other classes of therapies for IMIDs on SARS-CoV-2 vaccine immunogenicity.

Our findings have important implications for patients treated with anti-TNF drugs particularly those also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine unnecessarily exposes infliximab-treated patients to SARS-CoV-2 infection. However, because we observed higher rates of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even in the presence of TNF blockade, these patients should be prioritised for optimally timed second doses. Until patients receive a second dose of vaccine they should consider that they are not protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and shielding if appropriate.

Conclusion

Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with inflammatory bowel disease. Immunomodulators further blunted immunogenicity rates to both vaccines. Reassuringly,

347 vaccination after infection, or a second dose of vaccine led to seroconversion in most patients.
348 Delayed second dosing should be avoided in patients treated with infliximab.
349
350

351 **Table 1: Baseline characteristics of participants who had anti-SARS-CoV-2 spike antibodies**
352 **measured 3 to 10 weeks following primary vaccination against SARS-CoV-2**

Variable		Infliximab	Vedolizumab	Overall	p
Vaccine	BNT162b2	44·7% (387/865)	47·2% (202/428)	45·6% (589/1293)	0·41
	ChAdOx1 nCoV-19	55·3% (478/865)	52·8% (226/428)	54·4% (704/1293)	
Age (years)		41·4 (31·5 - 54·8)	49·6 (37·1 - 63·8)	43·8 (32·8 - 57·6)	<0·0001
Sex	Female	50·3% (434/863)	47·1% (200/425)	49·2% (634/1288)	0·19
	Male	49·7% (429/863)	52·7% (224/425)	50·7% (653/1288)	
	Intersex	0·0% (0/863)	0·0% (0/425)	0·0% (0/1288)	
	Prefer not to say	0·0% (0/863)	0·2% (1/425)	0·1% (1/1288)	
Ethnicity	White	91·8% (791/862)	89·9% (381/424)	91·1% (1172/1286)	0·62
	Asian	5·3% (46/862)	7·5% (32/424)	6·1% (78/1286)	
	Mixed	1·9% (16/862)	1·9% (8/424)	1·9% (24/1286)	
	Black	0·7% (6/862)	0·5% (2/424)	0·6% (8/1286)	
	Other	0·3% (3/862)	0·2% (1/424)	0·3% (4/1286)	
Diagnosis	Crohn's disease	65·4% (566/865)	40·7% (174/428)	57·2% (740/1293)	0·00050
	Ulcerative colitis or IBD-unclassified	34·6% (299/865)	59·3% (254/428)	42.8% (553/1293)	
Duration of IBD (years)		8·0 (4·0 - 16·0)	10·0 (5·0 - 17·8)	9·0 (4·0 - 16·0)	0·0040
Age at IBD diagnosis (years)		28·8 (21·6 - 41·8)	34·0 (23·3 - 47·6)	30·3 (21·9 - 43·7)	<0·0001
Immunomodulator		61·6% (533/865)	22·0% (94/427)	48·5% (627/1292)	<0·0001
5-ASA		23·0% (199/865)	31·6% (135/427)	25·9% (334/1292)	0·0012
Steroids		3·0% (26/865)	8·4% (36/427)	4·8% (62/1292)	<0·0001
BMI (kg/m^2)		25·9 (22·8 - 30·6)	26·1 (23·1 - 30·1)	26·0 (22·9 - 30·4)	0·75
Heart disease		3·6% (31/865)	6·5% (28/428)	4·6% (59/1293)	0·023
Diabetes		3·8% (33/865)	7·5% (32/428)	5·0% (65/1293)	0·0065
Lung disease		13·5% (117/865)	18·2% (78/428)	15·1% (195/1293)	0·032
Kidney disease		1·2% (10/865)	2·1% (9/428)	1·5% (19/1293)	0·22
Cancer		0·5% (4/865)	2·1% (9/428)	1·0% (13/1293)	0·013
Smoker	Yes	9·7% (84/862)	5·4% (23/425)	8·3% (107/1287)	0·0010
	Not currently	32·0% (276/862)	41·6% (177/425)	35·2% (453/1287)	
	Never	58·2% (502/862)	52·9% (225/425)	56·5% (727/1287)	
Exposure to documented cases of COVID-19		9·4% (81/862)	8·7% (37/425)	9·2% (118/1287)	0·76
Income deprivation score		0·086 (0·052 - 0·151)	0·084 (0·054 - 0·141)	0·086 (0·052 - 0·147)	0·94
Active disease (PRO2)		4·9% (41/831)	11·4% (46/405)	7·0% (87/1236)	<0·0001

353
354 **Abbreviations:** IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; BMI = Body Mass
355 Index; PRO2 = IBD disease activity. Values presented are median (interquartile range) or percentage
356 (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or
357 Fisher's exact test.

358 **Table 2: Univariable associations with anti-SARS-CoV-2 spike antibodies, stratified by**
359 **vaccine type**

Variable		BNT162b2		ChAdOx1 nCoV-19	
		Value	p	Value	p
Biologic treatment	Infliximab	6·0 (5·9)	<0·0001	4·7 (4·9)	<0·0001
	Vedolizumab	28·8 (5·4)		13·8 (5·9)	
Immunomodulator in infliximab-treated participants	No	9·7 (4·7)	<0·0001	5·7 (5·1)	0·045
	Yes	4·4 (6·3)		4·2 (4·7)	
Immunomodulator in vedolizumab-treated participants	No	32·4 (5·2)	0·052	15·6 (6·0)	0·082
	Yes	16·7 (6·3)		10·0 (5·5)	
Age (years)		rho = -0·22	<0·0001	rho = -0·15	<0·0001
Sex	Female	9·4 (7·0)	0·092	6·6 (5·5)	0·83
	Male	10·9 (6·3)		6·8 (5·7)	
Ethnicity	White	9·4 (6·6)	0·037	6·2 (5·6)	0·0051
	Asian	20·9 (7·3)		16·1 (5·2)	
	Mixed	25·7 (6·7)		13·7 (5·3)	
	Black	12·5 (1·6)		19·4 (2·2)	
	Other	22·9 (3·7)		5·7 (3·1)	
Diagnosis	Crohn's disease	7·3 (6·4)	<0·0001	5·6 (5·6)	0·0014
	Ulcerative colitis or IBD-unclassified	15·6 (6·5)		8·5 (5·5)	
Duration of IBD (years)		rho = -0·16	<0·0001	rho = -0·12	0·0013
Age at IBD diagnosis (years)		rho = -0·13	0·0021	rho = -0·04	0·25
5-ASA	No	9·8 (6·6)	0·40	6·7 (5·5)	0·93
	Yes	11·5 (7·1)		6·6 (5·9)	
Steroids	No	10·2 (6·7)	0·90	6·8 (5·5)	0·12
	Yes	10·7 (7·3)		4·1 (6·7)	
BMI (kg/m^2)		rho = -0·08	0·068	rho = -0·01	0·81
Heart disease	No	10·3 (6·7)	0·65	6·9 (5·6)	0·010
	Yes	8·7 (7·0)		2·8 (5·2)	
Diabetes	No	10·7 (6·7)	0·0028	6·8 (5·6)	0·066
	Yes	4·1 (4·6)		4·0 (5·2)	
Lung disease	No	10·1 (6·9)	0·70	6·9 (5·5)	0·31
	Yes	10·9 (5·7)		5·7 (6·1)	
Kidney disease	No	10·2 (6·6)	0·60	6·7 (5·5)	0·66
	Yes	15·6 (10·4)		4·7 (12·4)	
Cancer	No	10·4 (6·6)	0·13	6·7 (5·6)	0·069
	Yes	2·0 (9·2)		2·3 (3·6)	
Smoking	Yes	4·7 (7·1)	0·0077	3·4 (4·8)	0·00077
	Not currently	9·4 (6·6)		6·1 (5·4)	
	Never	11·8 (6·5)		8·0 (5·7)	
Exposure to documented cases of COVID-19	No	10·3 (6·7)	0·87	6·6 (5·5)	0·53
	Yes	9·8 (6·8)		7·8 (6·1)	
Income deprivation score		rho = 0·01	0·75	rho = 0·02	0·65
Active disease (PRO2)	No	10·1 (6·5)	0·32	6·6 (5·4)	0·51
	Yes	14·0 (7·6)		8·1 (7·0)	

360 **Abbreviations**: IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; VAS = visual
361 analogue scale. Values presented are geometric mean antibody concentration (geometric standard
362 deviation) or Spearman's rho. P values represent the results of an unpaired t test or test of
363 Spearman's rho.

364 **Figure Captions**

365 **Figure 1:** Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs
366 vedolizumab) and type of vaccine. The wider bar represents the geometric mean, while the narrower
367 bars are drawn one geometric standard deviation either side of the geometric mean. The threshold
368 shown of 15 U/mL is the one used to determine seroconversion.

369 **Figure 2:** Exponentiated coefficients of linear regression models of log(anti-SARS-CoV-2 spike
370 antibody concentration). The resultant values represent the fold change of antibody concentration
371 associated with each variable. Each vaccine was modelled separately, and then a further model was
372 created using all of the available data.

373 **Figure 3:** Rolling geometric mean antibody concentration over time stratified by biologic therapy
374 (infliximab vs vedolizumab) and vaccine. Geometric means are calculated using a rolling 15 day
375 window (i.e. 7 days either side of the day indicated). The shaded areas represent the 95% confidence
376 intervals of the geometric means. Overall, data from 2126 participants (1427 on infliximab and 699
377 on vedolizumab) are included in this graph between 1 and 63 days post vaccination.

378 **Figure 4:** Percentages of participants with seroconversion defined by an anti-SARS-CoV-2 spike
379 antibody concentration ≥ 15 U/mL, stratified by vaccine, biologic and immunomodulator use. Error
380 bars represent the 95% confidence interval of the percentages. **Abbreviations**: IMM =
381 immunomodulator

382 **Figure 5:** Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs
383 vedolizumab), prior infection, number of doses and type of vaccine. The wider bar represents the
384 geometric mean, while the narrower bars are drawn one geometric standard deviation either side of
385 the geometric mean. The threshold shown of 15 U/mL is the one used to determine seroconversion.

Contributions

NAK, JRG, CB, SS, NP, TA participated in the conception and design of this study. CB was the project manager and coordinated patient recruitment. RN and TJM coordinated all biochemical analyses and central laboratory aspects of the project. NAK, SL, JRG, NC, BH, DC, JRF, AF, PMI, NK, KBK, CAL, JM, SJM, RCGP, TR, PJS, AMV, TJM, SS, CWL, NP, TA were involved in the acquisition, analysis, or interpretation of data. Data analysis was done by NAK. Drafting of the manuscript was done by NAK, SL, JRG, NC, RN, DC, RCGP, SS, CWL, NP, TA. SS, NP and TA obtained the funding for the study. All the authors contributed to the critical review and final approval of the manuscript. NAK and TA have verified the underlying data.

Declarations of interest

Dr. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the conduct of the study; grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside the submitted work. Dr. Lin reports non-financial support from Pfizer, non-financial support from Ferring, outside the submitted work. Dr. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the conduct of the study. Dr. Chee reports non-financial support from Ferring, personal fees and non-financial support from Pfizer, outside the submitted work. Dr. Cummings reports grants and personal fees from Samsung, Pfizer & Biogen; personal fees and non-financial support from Janssen & Abbvie; grants, personal fees and non-financial support from Takeda; personal fees from MSD, Sandoz, Celltrion & NAPP, outside the submitted work. Dr. Irving reports grants and personal fees from Takeda, grants from MSD, grants and personal fees from Pfizer, personal fees from Galapagos,

410 personal fees from Gilead, personal fees from Abbvie, personal fees from Janssen, personal fees
411 from Boehringer Ingelheim, personal fees from Topivert, personal fees from VH2, personal fees from
412 Celgene, personal fees from Arena, personal fees from Samsung Bioepis, personal fees from Sandoz,
413 personal fees from Procise, personal fees from Prometheus, outside the submitted work. Dr.
414 Kamperidis reports personal fees from Janssen, outside the submitted work. Dr. Kok reports
415 personal fees from Janssen, personal fees from Takeda, personal fees from PredictImmune, personal
416 fees from Amgen, outside the submitted work. Dr. Lamb reports grants from Genentech, grants and
417 personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie, personal
418 fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from UCB
419 Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ, personal
420 fees from Dr Falk Pharma, grants from AstraZeneca, outside the submitted work. Dr. Macdonald
421 reports grants and personal fees from Takeda Pharmaceuticals, grants and personal fees from
422 Biogen, personal fees and non-financial support from AbbVie, personal fees from Grifols, personal
423 fees from Sandoz, personal fees from Celltrion, personal fees and non-financial support from
424 Janssen, personal fees from Vifor Pharmaceuticals, personal fees from Predictimmune, personal fees
425 from Bristol Myers Squibb, non-financial support from Ferring Pharmaceuticals, outside the
426 submitted work. Prof. Pollok reports acting as consultant, advisory board member, speaker or
427 recipient of educational grant from Dr Falk, Ferring, Janssen, Pharmacosmos and Takeda. Dr. Raine
428 reports grants and personal fees from Abbvie, personal fees from BMS, personal fees from Celgene,
429 personal fees from Ferring, personal fees from Gilead, personal fees from GSK, personal fees from
430 LabGenius, personal fees from Janssen, personal fees from Mylan, personal fees from MSD, personal
431 fees from Novartis, personal fees from Pfizer, personal fees from Sandoz, personal fees from Takeda,
432 personal fees from Galapagos, personal fees from Arena, outside the submitted work. Dr Smith
433 reports speaker fees and advisory board sponsorship from Janssen, Celltrion and Takeda outside the
434 submitted work. Dr. Verma reports personal fees and non-financial support from Takeda, personal

435 fees and non-financial support from Celltrion, personal fees and non-financial support from Merck
436 Sharp & Dohme, outside the submitted work. Prof. Sebastian reports grants from Takeda, Abbvie,
437 AMGEN, Tillots Pharma, personal fees from Jaansen, Takeda, Galapagos, Celltrion, Falk Pharma,
438 Tillots pharma, Cellgene, Pfizer, Pharmacocosmos, outside the submitted work. Prof. Lees reports
439 personal fees from Abbvie, personal fees from Janssen, personal fees from Pfizer, personal fees from
440 Takeda, grants from Gilead, personal fees from Gilead, personal fees from Galapagos, personal fees
441 from Iterative Scopes, personal fees from Trellus Health, personal fees from Celltion, personal fees
442 from Ferring, personal fees from BMS, during the conduct of the study. Dr. Powell reports personal
443 fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees from Bristol-
444 Myers Squibb, personal fees from Abbvie, personal fees from Roche, personal fees from Lilly,
445 personal fees from Allergan, personal fees from Celgene, outside the submitted work; and Dr. Powell
446 has served as a speaker/advisory board member for Abbvie, Allergan, Bristol Myers Squibb, Celgene,
447 Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda and Vifor Pharma. Prof. Ahmad reports grants and non-
448 financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion
449 Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, during the
450 conduct of the study; personal fees from Biogen inc, grants and personal fees from Celltrion
451 Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from
452 Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram
453 Healthcare, personal fees from Pfizer, personal fees from Genentech, non-financial support from
454 Tillotts, outside the submitted work. The following authors have nothing to declare: Neil Chanchlani,
455 Ben Hamilton, Claire Bewshea, Rachel Nice, Shameer J Mehta, Timothy J McDonald.

456

457 **Acknowledgements**

458 CLARITY IBD is a UK National Institute for Health Research (NIHR) Urgent Public Health Study. The
459 NIHR Clinical Research Network supported study set-up, site identification, and delivery of this study.
460 This was facilitated by Professor Mark Hull, the National speciality lead for Gastroenterology. We
461 acknowledge the contribution of our Patient Advisory Group who helped shape the trial design
462 around patient priorities. Our partners, Crohn's and Colitis UK (CCUK), continue to support this
463 group and participate in Study Management Team meetings. We thank Professor Danny Altmann,
464 Professor Rosemary Boyton, Professor Graham Cooke and Dr Katrina Pollock for their helpful
465 discussions and review of the data. Laboratory tests were undertaken by the Exeter Blood Sciences
466 Laboratory at the Royal Devon and Exeter NHS Foundation Trust. The Exeter NIHR Clinical Research
467 Facility coordinated sample storage and management. Tariq Malik and James Thomas from Public
468 Health England, Guy Stevens, Katie Donelon, Elen de Lacy from Public Health Wales and Johanna
469 Bruce from Public Health Scotland supported linkage of central SARS-CoV-2 PCR test results with
470 study data. Roche Diagnostics Limited provided the Elecsys Anti-SARS-CoV-2 immunoassay for the
471 study. SL is supported by a Wellcome GW4-CAT fellowship. NC acknowledges support from CCUK.
472 CAL acknowledges support from the NIHR Newcastle Biomedical Research Centre and the support of
473 the Programmed Investigation Unit at Royal Victoria Infirmary, Newcastle upon Tyne. TR
474 acknowledges support with recruitment from the NIHR Cambridge BRC. CWL is funded by a UKRI
475 Future Leaders Fellowship. NP is supported by the NIHR Imperial Biomedical Research Center (BRC).
476 We acknowledge the study co-ordinators of the Exeter Inflammatory Bowel Disease Research Group:
477 Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative support to the study.
478 The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust.

Patient involvement

We conducted an electronic survey to gauge the opinion of patients with IBD on the patient questionnaires to be delivered as part of the CLARITY IBD study. We surveyed 250 patients across 74 hospitals. All our proposed questions for study inclusion were rated as important or very important by at least 83% of participants. The Exeter IBD Patient Panel refined the questions included in the study questionnaire, reviewed the study protocol, supported the writing of the patient information sheets, and participated in testing of the electronic consent form and patient questionnaire. A member of the Exeter IBD Patient Panel sits on the study management committee, ensuring patient involvement in all aspects of study delivery, data analysis and dissemination of findings.

Data sharing

The study protocol including the statistical analysis plan is available at www.clarityibd.org. Individual participant de-identified data that underlie the results reported in this article will be available immediately after publication for a period of 5 years. The data will be made available to investigators whose proposed use of the data has been approved by an independent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to tariq.ahmad1@nhs.net. To gain access data requestors will need to sign a data access agreement.

497 ## References

498 1 Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination
499 programme for maximum short-term impact. 2021.
500 https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-
501 jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-
502 impact (accessed March 20, 2021).
503 2 European Centre for Disease Prevention and Control. Overview of the implementation of
504 COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. 2021.
505 3 National Advisory Committee on Immunization. COVID-19 vaccine extended dose interval for
506 Canadians. 2021. https://www.canada.ca/en/public-health/services/immunization/national-
507 advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-
508 19-vaccines-early-rollout-population-protection.html (accessed March 22, 2021).
509 4 Jones GR, Lyons M, Plevris N, *et al.* IBD prevalence in Lothian, Scotland, derived by capture-
510 recapture methodology. *Gut* 2019; **68**: 1953–60.
511 5 Hamilton B, Green H, Heerasing N, *et al.* Incidence and prevalence of inflammatory bowel
512 disease in Devon, UK. *Frontline Gastroenterol* 2020; published online June 24.
513 DOI:10.1136/flgastro-2019-101369.
514 6 Melmed GY, Agarwal N, Frenck RW, *et al.* Immunosuppression Impairs Response to
515 Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. *Am J*
516 *Gastroenterol* 2010; **105**: 148–54.
517 7 Caldera F, Hillman L, Saha S, *et al.* Immunogenicity of High Dose Influenza Vaccine for Patients
518 with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.
519 *Inflamm Bowel Dis* 2019; **26**: 593–602.
520 8 Pratt PK, David N, Weber HC, *et al.* Antibody Response to Hepatitis B Virus Vaccine is
521 Impaired in Patients with Inflammatory Bowel Disease on Infliximab Therapy. *Inflamm Bowel*
522 *Dis* 2018; **24**: 380–6.
523 9 Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients
524 with inflammatory bowel disease. *Am J Gastroenterol* 2013; **108**: 240–8.
525 10 Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK. The Immunogenicity of the
526 Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel
527 Disease Treated With Vedolizumab. *Crohn's Colitis 360* 2020; **2**. DOI:10.1093/crocol/otaa082.
528 11 Kennedy NA, Goodhand JR, Bewshea C, *et al.* Inflammatory bowel disease Anti-SARS-CoV-2
529 antibody responses are attenuated in patients with IBD treated with infliximab. *Gut* 2021; **0**:
530 1–11.
531 12 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international
532 community of software platform partners. J. Biomed. Inform. 2019; **95**.
533 DOI:10.1016/j.jbi.2019.103208.
534 13 Roche Diagnostics GmbH. Elecsys® Anti-SARS-CoV-2 S assay method sheet. 2020.
535 https://diagnostics.roche.com/gb/en/products/params/elecsys-anti-sars-cov-2-s.html
536 (accessed March 24, 2021).
537 14 Muench P, Jochum S, Wenderoth V, *et al.* Development and validation of the elecsys anti-
538 SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-
539 CoV-2. *J Clin Microbiol* 2020; **58**: 1694–714.
540 15 Rubio-Acero R, Castelletti N, Fingerle V, *et al.* In search for the SARS-CoV-2 protection
541 correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-
542 characterized oligo-/asymptomatic patients. *medRxiv* 2021; : 2021.02.19.21252080.
543 16 L'Huillier AG, Meyer B, Andrey DO, *et al.* Antibody persistence in the first 6 months following
544 SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin*

Microbiol Infect 2021; **0**. DOI:10.1016/j.cmi.2021.01.005.

17 Alexander JL, Moran GW, Gaya DR, *et al.* SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. *Lancet Gastroenterol Hepatol* 2021; **6**: 218–24.

18 Boyarsky BJ, Werbel WA, Avery RK, *et al.* Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA* 2021; published online March 15. DOI:10.1001/jama.2021.4385.

19 Monin-Aldama L, Laing AG, McKenzie DR, *et al.* Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. *medRxiv* 2021; : 2021.03.17.21253131.

20 Choi B, Choudhary MC, Regan J, *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med* 2020; **383**: 2291–3.

21 Avanzato VA, Matson MJ, Seifert SN, *et al.* Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell* 2020; **183**: 1901-1912.e9.

22 Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. *Vaccine* 1994; **12**: 771–2.

23 MacKenzie JS, MacKenzie IH, Holt PG. The effect of cigarette smoking on susceptibility to epidemic influenza and on serological responses to live attenuated and killed subunit influenza vaccines. *J Hyg (Lond)* 1976; **77**: 409–17.

24 Haralambieva IH, Ovsyannikova IG, Umlauf BJ, *et al.* Genetic polymorphisms in host antiviral genes: Associations with humoral and cellular immunity to measles vaccine. *Vaccine* 2011; **29**: 8988–97.

25 Huda MN, Lewis Z, Kalanetra KM, *et al.* Stool microbiota and vaccine responses of infants. *Pediatrics* 2014; **134**: e362–72.

26 Savy M, Edmond K, Fine PEM, *et al.* Landscape analysis of interactions between nutrition and vaccine responses in children. *J Nutr* 2009; **139**. DOI:10.3945/jn.109.105312.

27 Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNFα-deficient mice: A critical requirement for TNFα in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. *J Exp Med* 1996; **184**: 1397–411.

28 Ritter U, Meissner A, Ott J, Körner H. Analysis of the maturation process of dendritic cells deficient for TNF and lymphotoxin-α reveals an essential role for TNF. *J Leukoc Biol* 2003; **74**: 216–22.

29 Marot S, Malet I, Leducq V, *et al.* Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. *Nat Commun* 2021; **12**: 1–7.

30 Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *JAMA* 2021; published online March 19. DOI:10.1001/jama.2021.4388.


BNT162b2
ChAdOx1 nCoV-19
387
202
478
226
1000
100
10
1
Anti-SARS-CoV-2 S
Infliximab
Vedolizumab
Infliximab
Vedolizumab
Biologic

BNT162b2

Variable	N	Fold change (95% CI)	p
Infliximab (vs vedolizumab)	386/587	0·29 (0·21, 0·40)	<0·0001
Immunomodulator	269/587	0·41 (0·31, 0·55)	<0·0001
Crohn's disease (vs UC or IBDU)	327/587	0·75 (0·57, 1·00)	0·046
Age ≥ 60	113/587	0·34 (0·24, 0·47)	<0·0001
Non-white ethnicity	61/587	1·81 (1·16, 2·81)	0·0085
Current smoker	44/587	0·52 (0·31, 0·86)	0·011



ChAdOx1 nCoV-19

Variable	N	Fold change (95% CI)	p
Infliximab (vs vedolizumab)	475/697	0·39 (0·30, 0·51)	<0·0001
Immunomodulator	355/697	0·65 (0·50, 0·84)	0·00085
Crohn's disease (vs UC or IBDU)	409/697	0·85 (0·66, 1·09)	0·20
Age ≥ 60	162/697	0·48 (0·36, 0·65)	<0·0001
Non-white ethnicity	55/697	2·04 (1·31, 3·17)	0·0017
Current smoker	63/697	0·55 (0·36, 0·84)	0·0059

All

Variable	N	Fold change (95% CI)	p
Infliximab (vs vedolizumab)	861/1284	0·34 (0·27, 0·41)	<0·0001
Immunomodulator	624/1284	0·51 (0·42, 0·62)	<0·0001
Crohn's disease (vs UC or IBDU)	736/1284	0·79 (0·66, 0·96)	0·015
Age ≥ 60	275/1284	0·40 (0·32, 0·50)	<0·0001
Non-white ethnicity	116/1284	1·95 (1·43, 2·67)	<0·0001
Current smoker	107/1284	0·53 (0·39, 0·74)	0·00016


BNT162b2
ChAdOx1 nCoV-19
Anti-SARS-CoV-2 S antibody concentration (U/mL)
30
10
3
1
0.0
2.5
5.0
7.5
Weeks since vaccine
Biologic
Infliximab
Vedolizumab


BNT162b2
ChAdOx1 nCoV-19
Percent seropositive
100%
75%
50%
25%
0%
27.1%
65/240
36.1%
53/147
55.6%
20/36
74.7%
124/166
20.2%
60/297
27.6%
50/181
45.2%
28/62
57.3%
94/164
Infliximab with IMM
Infliximab without IMM
Vedolizumab with IMM
Vedolizumab without IMM
Infliximab with IMM
Infliximab without IMM
Vedolizumab with IMM
Vedolizumab without IMM


BNT162b2
Infliximab
BNT162b2
Vedolizumab
ChAdOx1 nCoV-19
Infliximab
ChAdOx1 nCoV-19
Vedolizumab
387
51
20
202
15
7
478
42
226
19
Anti-SARS-CoV-2 S U/mL
10000
1000
100
10
1
One dose, no prior infection
One dose, prior infection
Two doses